- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Chronic migraine
- Meeting Date: March 2022
- Public Summary Document (PSD) March 2022 PBAC Meeting - (PDF 364KB)
- Public Summary Document (PSD) March 2022 PBAC Meeting - (Word 49KB)
Fremanezumab – March 2022
Fremanezumab (auto-injector): Solution for injection 225 mg in 1.5 mL single dose auto-injector; Ajovy®
Last updated
30 May 2025